• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams Imidolactams
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidolactams

1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine: An Emerging Compound in Pharmaceutical Research

1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine (CAS No. 1344188-66-4) is a novel compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the class of pyrazoles, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and anticonvulsant properties.

The chemical structure of 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine features a pyrazole ring linked to an oxolan derivative through a methoxyethyl group. This specific arrangement of functional groups imparts the compound with unique pharmacological properties that are currently being explored in various preclinical and clinical studies.

Recent research has highlighted the potential of 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine as a promising candidate for the treatment of neurodegenerative diseases. Studies have shown that this compound exhibits neuroprotective effects by modulating key signaling pathways involved in neuronal survival and function. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine can effectively inhibit the activation of microglia, which are immune cells in the brain that contribute to neuroinflammation when overactivated.

In addition to its neuroprotective properties, 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine has also shown promise in the treatment of pain and inflammation. Preclinical studies have reported that this compound exhibits potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. These findings suggest that 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine could be a valuable therapeutic option for conditions such as rheumatoid arthritis and chronic pain syndromes.

The pharmacokinetic profile of 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine is another area of active research. Studies have shown that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) properties, making it suitable for oral administration. Additionally, its low toxicity and high selectivity for target receptors further enhance its potential as a safe and effective therapeutic agent.

In the context of drug development, the synthesis and optimization of 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine have been extensively studied to improve its efficacy and reduce potential side effects. Researchers have employed various synthetic strategies to modify the chemical structure of this compound, leading to the development of several analogs with enhanced biological activities. For example, a recent study published in Organic & Biomolecular Chemistry reported the synthesis of a series of derivatives with improved solubility and bioavailability.

The clinical potential of 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine is further supported by ongoing clinical trials. Phase I trials have demonstrated that this compound is well-tolerated by patients and exhibits a favorable safety profile. These findings have paved the way for more advanced clinical studies to evaluate its efficacy in treating specific diseases.

In conclusion, 1-{2-(Oxolan-2-yl)methoxyethyl}-1H-pyrazol-3-amine (CAS No. 1344188-66-4) represents a promising candidate in pharmaceutical research with potential applications in neuroprotection, pain management, and inflammation control. Its unique chemical structure and favorable pharmacological properties make it an attractive target for further investigation and development as a therapeutic agent.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)